These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16575006)

  • 21. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
    Goto H; Keshelava N; Matthay KK; Lukens JN; Gerbing RB; Stram DO; Seeger RC; Reynolds CP
    Med Pediatr Oncol; 2000 Dec; 35(6):619-22. PubMed ID: 11107131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
    Sartelet H; Imbriglio T; Nyalendo C; Haddad E; Annabi B; Duval M; Fetni R; Victor K; Alexendrov L; Sinnett D; Fabre M; Vassal G
    Histopathology; 2012 Jun; 60(7):1144-55. PubMed ID: 22394107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.
    Fletcher JI; Gherardi S; Murray J; Burkhart CA; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M
    Cancer Res; 2012 Feb; 72(4):845-53. PubMed ID: 22202125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
    Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
    Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
    Weber A; Starke S; Bergmann E; Christiansen H
    Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYCN gene amplification in patients with neuroblastic tumors.
    Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
    Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach.
    H'Mida Ben Brahim D; Trabelsi S; Chabchoub I; Gargouri I; Harrabi I; Moussa A; Chourabi M; Haddaji M; Sassi S; Mougou S; Gribaa M; Ben Ahmed S; Zakhama A; Nouri A; Saad A
    Tunis Med; 2015; 93(8-9):527-31. PubMed ID: 26815518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.